Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
-
- STATUS
- Not Recruiting
-
- participants needed
- 2000
-
- sponsor
- Genfit
Updated on 26 January 2021
GENFIT
Primary Contact
Dim Clinica Privada (3.1 mi away) Contact
+322 other locationSummary
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
Details
| Condition | Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Nonalcoholic Steatohepatitis (NASH) With Fibrosis |
|---|---|
| Treatment | Placebo, Elafibranor |
| Clinical Study Identifier | NCT02704403 |
| Sponsor | Genfit |
| Last Modified on | 26 January 2021 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer